Literature DB >> 15368106

Pathogenesis and treatment of neoplastic diseases of the papilla of Vater: Kausch-Whipple procedure with lymph node dissection in cancer of the papilla of Vater.

Hans G Beger1, F Chikh Thorab, Z Liu, N Harada, B M Rau.   

Abstract

Cancer of the papilla or the ampulla of Vater appears, from a clinical point of view, to be an intraduodenal or ampullary cancer. An adenoma-dysplasia-carcinoma sequence has been established. In 20%-40% of the patients with an adenoma of the papilla, a cancerous lesion in the adenoma is additionally observed. Oncological resection using a Kausch-Whipple technique or a pylorus-preserving partial pancreatico-duodenectomy (PPPD) offers a 5-year survival probability of between 45% and 65%. The hospital mortality after oncological resection at experienced centers is below 5%. The most frequent treatment-related complication is pancreatic fistula, which occurs in around 20% of the patients. In about 10% of the patients with a pT1 cancer and in 25% to 67% with pT2 and pT3 cancer, lymph node involvement has been observed. Lymph nodes in front of and behind the head of the pancreas are the primary targets for cancer cell disseminations. In more than one-third of the patients, lymph nodes in the inter-aortocaval space and the lymph nodes around the superior mesenteric artery and the nodes in the pancreatic segment of the hepatoduodenal ligament are involved. Therefore, tissue dissection, including, selectively, the N2 lymph nodes, is an essential component of radical surgery for cancer of the papilla. A standard Kausch-Whipple resection or PPPD without a selective extended lymph node dissection, including the interaortocaval and superior mesenteric artery nodes, results in about 30% of the patients having an R2-resection, i.e., with cancer left behind. The long-term survival is determined by the tumor biological factors: (1) absence of lymph node involvement and (2) absence of infiltration into the pancreas. The surgeon's contribution to the cure of cancer of the papilla is to perform an R0-resection with low hospital mortality and low postoperative morbidity. Patients without lymph node involvement, and with absence of infiltration into the pancreas, no lymph vessel invasion, and tumor-negative margins have major benefits from oncological resection in regard to curability of the cancer.

Entities:  

Mesh:

Year:  2004        PMID: 15368106     DOI: 10.1007/s00534-004-0895-6

Source DB:  PubMed          Journal:  J Hepatobiliary Pancreat Surg        ISSN: 0944-1166


  10 in total

1.  Gallbladder perforation associated with carcinoma of the duodenal papilla: a case report.

Authors:  Akihiro Hosaka; Mikiko Nagayoshi; Katsuyoshi Sugizaki; Yukiyoshi Masaki
Journal:  World J Surg Oncol       Date:  2010-05-20       Impact factor: 2.754

2.  Safety and long-term follow-up of endoscopic snare excision of ampullary adenomas.

Authors:  P Katsinelos; G Paroutoglou; J Kountouras; A Beltsis; B Papaziogas; K Mimidis; C Zavos; S Dimiropoulos
Journal:  Surg Endosc       Date:  2006-02-27       Impact factor: 4.584

Review 3.  Review of the investigation and surgical management of resectable ampullary adenocarcinoma.

Authors:  James Askew; Saxon Connor
Journal:  HPB (Oxford)       Date:  2013-01-10       Impact factor: 3.647

4.  Coexistence of small cell neuroendocrine carcinoma and villous adenoma in the ampulla of Vater.

Authors:  Ji-Hong Sun; Ming Chao; Shi-Zheng Zhang; Guang-Qiang Zhang; Bin Li; Jian-Jun Wu
Journal:  World J Gastroenterol       Date:  2008-08-07       Impact factor: 5.742

5.  Frequency and prognostic significance of occult tumor cells in lymph nodes in patients with adenocarcinoma of the papilla of Vater.

Authors:  P Scheunemann; N H Stoecklein; A Rehders; M Bidde; S Metz; M Peiper; C Eisenberger; J Schulte Am Esch; W T Knoefel; S B Hosch
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

6.  Prognostic microRNAs in cancer tissue from patients operated for pancreatic cancer--five microRNAs in a prognostic index.

Authors:  Nicolai A Schultz; Klaus K Andersen; Anne Roslind; Hanni Willenbrock; Morten Wøjdemann; Julia S Johansen
Journal:  World J Surg       Date:  2012-11       Impact factor: 3.352

7.  A seven-miRNA expression-based prognostic signature and its corresponding potential competing endogenous RNA network in early pancreatic cancer.

Authors:  Xue Bai; Donglan Lu; Yan Lin; Yufeng Lv; Liusheng He
Journal:  Exp Ther Med       Date:  2019-07-03       Impact factor: 2.447

8.  Guidelines for the management of biliary tract and ampullary carcinomas: surgical treatment.

Authors:  Satoshi Kondo; Tadahiro Takada; Masaru Miyazaki; Shuichi Miyakawa; Kazuhiro Tsukada; Masato Nagino; Junji Furuse; Hiroya Saito; Toshio Tsuyuguchi; Masakazu Yamamoto; Masato Kayahara; Fumio Kimura; Hideyuki Yoshitomi; Satoshi Nozawa; Masahiro Yoshida; Keita Wada; Satoshi Hirano; Hodaka Amano; Fumihiko Miura
Journal:  J Hepatobiliary Pancreat Surg       Date:  2008-02-16

9.  Downregulation of USP34 Inhibits the Growth and Migration of Pancreatic Cancer Cells via Inhibiting the PRR11.

Authors:  Changjie Lin; Jing Xia; Zhiwei Gu; Yunpeng Meng; Dekang Gao; Shaohua Wei
Journal:  Onco Targets Ther       Date:  2020-02-18       Impact factor: 4.147

10.  Choice of surgical procedures for patients with stage T1 carcinoma of the papilla of Vater: a retrospective study.

Authors:  Zongting Gu; Zongze Li; Wenlong Yu; Yongjie Zhang; Chengfeng Wang
Journal:  Transl Cancer Res       Date:  2020-11       Impact factor: 1.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.